Intravenous Iron Drugs Market

Market Definition

The market focuses on the production, distribution, and sale of iron-based injectable therapies primarily used to treat iron deficiency anemia. It encompasses pharmaceutical companies, healthcare providers, and distribution networks, characterized by product innovation, regulatory compliance, and strategic expansion to meet the clinical demand for intravenous iron treatments. 

The report provides insights into the core drivers of market growth, supported by an in-depth evaluation of industry trends and regulatory frameworks.

Intravenous Iron Drugs Market Overview

Global intravenous iron drugs market size was valued at USD 3140.0 million in 2024, which is estimated to be USD 3408.2 million in 2025 and reach USD 6174.4 million by 2032, growing at a CAGR of 8.77% from 2025 to 2032. 

Newly formed specialty pharmaceutical companies are accelerating market growth through focused commercialization strategies. Companies such as Pharmacosmos Therapeutics, Inc. concentrate on intravenous iron therapies, enabling quicker market penetration, enhanced brand presence, and improved access to treatments for iron deficiency anemia.

Major companies operating in the intravenous iron drugs industry are AbbVie Inc., Covis Pharma GmbH., Daiichi Sankyo, Inc., Sanofi , CSL Vifor, PHARMACOSMOS A/S , Zydus Lifesciences Limited, Cadila Pharmaceuticals, Sandoz AG, AdvaCare Pharma, SHREEJI PHARMA INTERNATIONAL , Livealth, Dr. Reddy’s Laboratories Ltd. , Pace Biotech, and Matinspharma.

The growing prevalence of anemia has led to a significant rise in demand for effective treatment solutions, fueling market expansion.

• In February 2025, World Health Organization (WHO) identified anemia as a major public health concern, primarily caused by iron deficiency. It results from poor nutrition, infections, or chronic conditions. Globally, anemia affects 40% of children aged 6–59 months, 37% of pregnant women, and 30% of women aged 15–49.

Intravenous iron therapies are increasingly favored for their rapid and efficient correction of iron deficiency, particularly in cases where oral supplementation is ineffective or unsuitable. The market is witnessing consistent growth, supported by advancements in drug formulations, improved healthcare infrastructure, and increased awareness among healthcare providers and patients regarding the benefits of intravenous iron administration.

Key Highlights:

1. The intravenous iron drugs market size was recorded at USD 3140.0 million in 2024.
2. The market is projected to grow at a CAGR of 8.77% from 2025 to 2032.
3. North America held a market share of 34.09% in 2024, with a valuation of USD 1070.3 million.
4. The iron dextran segment garnered USD 1137.3 million in revenue in 2024.
5. The chronic kidney disease segment is expected to reach USD 2033.0 million by 2032.
6. The retail pharmacy segment is anticipated to witness the fastest CAGR of 8.89% over the forecast period
7. Asia Pacific is anticipated to grow at a CAGR of 9.78% through the projection period.

Market Driver

Focused Commercialization Strategies

The market is witnessing significant growth, largely propelled by the focused commercialization strategies of emerging specialty pharmaceutical companies. These firms concentrate exclusively on the development and distribution of intravenous iron therapies, allowing for targeted investment in marketing, sales, and clinical outreach. 

With dedicated leadership teams and strategic go-to-market plans, they effectively address unmet clinical needs, enhance brand visibility, and strenghthen relationships with healthcare providers, accelerating product adoption and expanding market presence in key regions.

• In August 2024, Pharmacosmos established Pharmacosmos Therapeutics, Inc. in the U.S. to focus exclusively on the commercialization of intravenous iron treatments for iron deficiency anemia. This move strengthens their global presence and marks a strategic entry into the growing US market, with a dedicated leadership team and aim to address unmet clinical needs.

Market Challenge

High Treatment Costs

High treatment costs remain a significant challenge to the progress of the intravenous iron drugs market, as these therapies are considerably more expensive than oral alternatives, limiting accessibility in low- and middle-income regions. This cost barrier restricts widespread adoption despite clinical benefits. 

To address this, pharmaceutical companies and healthcare systems can explore strategies such as tiered pricing models, public-private partnerships, and insurance coverage expansion. Additionally, increasing local manufacturing capabilities and supporting government health programs can help reduce costs and improve access to intravenous iron treatments globally.

Market Trend

Rising Focus on Maternal Health

The growing emphasis on maternal health is emerging as a significant trend in the market. Iron deficiency anemia (IDA), a major cause of maternal morbidity and mortality, particularly during late pregnancy and postpartum hemorrhage (PPH), is fueling adoption of intravenous iron therapies.

These treatments offer rapid iron replenishment for women who cannot tolerate or respond to oral supplements. This trend aligns with national health programs prioritizing maternal and neonatal outcomes.

• In May 2023, Emcure Pharmaceuticals launched Orofer FCM 750, an advanced ferric carboxymaltose-based intravenous iron therapy. Designed for patients with hemoglobin below 10 g/dl, this formulation enhances treatment convenience and aligns with India's efforts to address iron deficiency anemia, particularly in pregnant and postpartum women.

Intravenous Iron Drugs Market Report Snapshot

Segmentation	Details
By Product	Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Others
By Application	Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Others
By Distribution Channel	Hospitals, Retail Pharmacy, Online
By Region	North America: U.S., Canada, Mexico
	Europe: France, UK, Spain, Germany, Italy, Russia, Rest of Europe
	Asia-Pacific: China, Japan, India, Australia, ASEAN, South Korea, Rest of Asia-Pacific
	Middle East & Africa: Turkey, U.A.E., Saudi Arabia, South Africa, Rest of Middle East & Africa
	South America: Brazil, Argentina, Rest of South America

Market Segmentation

• By Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Others): The iron dextran segment earned USD 1137.3 million in 2024 due to its widespread use in treating iron deficiency anemia and its cost-effectiveness in chronic disease management.
• By Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Others): The chronic kidney disease segment held a share of 33.24% in 2024, due to the high prevalence of anemia among CKD patients and increasing intravenous iron therapy adoption.
• By Distribution Channel (Hospitals, Retail Pharmacy, Online): The hospitals segment is projected to reach USD 2576.2 million by 2032,  owing to rising inpatient treatments, better access to IV administration, and enhanced clinical monitoring facilities.

Intravenous Iron Drugs Market Regional Analysis

Based on region, the global market has been classified into North America, Europe, Asia Pacific, Middle East & Africa, and South America.

North America intravenous iron drugs market share stood at around 34.09% in 2024, valued at USD 1070.3 million. This dominances is fueled by its advanced healthcare infrastructure, high prevalence of iron deficiency anemia, and strong adoption of innovative therapies. 

The regional market further benefits from extensive clinical research, supportive regulatory frameworks, and significant healthcare spending. Increasing awareness among healthcare providers and patients regarding the limitations of oral iron supplements is fostering the shift toward intravenous treatments. 

Additionally, favorable reimbursement policies and the presence of leading pharmaceutical companies contribute to sustained regional market growth.

• In March 2024, Health Canada approved Ferinject (ferric carboxymaltose) for intravenous treatment of iron deficiency anemia in adults and children, including patients with heart failure. The approval expands access to effective IV iron therapy in cases where oral iron is ineffective or poorly tolerated, supporting improved patient outcomes.

The Asia-Pacific intravenous iron drugs industry is poised to grow at a CAGR of 9.78% over the forecast period. This growth is propelled by a rising prevalence of iron deficiency anemia, increasing healthcare awareness, and expanding healthcare infrastructure. 

Rapid urbanization, improving access to advanced medical treatments, and growing government initiatives to combat anemia, particulalry among vulnerable populations such as women and children, are fueling demand. Additionally, expanding pharmaceutical manufacturing and favorable regulatory environments in countries such as India and China are fostering regional market growth.

Regulatory Frameworks

• In the U.S., the Food and Drug Administration (FDA) ensures public health by regulating the safety, efficacy, and security of medical devices, including intravenous hydration products. The FDA oversees approval processes, quality standards, and compliance to protect patients and maintain market safety.
• In the EU, IV devices require CE marking to demonstrate conformity with essential safety and performance requirements, allowing legal market access across member countries.
• In India, intravenous hydration devices are regulated under the Medical Devices Rules, 2017 by Central Drugs Standard Control Organization (CDSCO). Companies are required to obtain licenses and comply with quality standards, performance evaluations, and post-market surveillance to ensure safety and effectiveness in healthcare settings.

Competitive Landscape

Pharmaceutical companies are contributing significantly to the expansion of the intravenous iron drugs market by advancing iron deficiency treatments through innovative product launches, extensive clinical trials, and strategic partnerships. They are focusing on developing safer, more effective intravenous iron therapies that offer improved patient tolerability and rapid efficacy. 

Large-scale studies aim to expand indications and secure regulatory approvals in key markets, while companies invest in educating healthcare providers and patients on the benefits of treating iron deficiency in conditions such as heart failure, chronic kidney disease, and anemia.

• In June 2023, the FDA approved Injectafer (ferric carboxymaltose) by CSL Vifor for treating iron deficiency in adult patients with heart failure (NYHA class II/III) to improve exercise capacity. It is the first intravenous iron therapy approved for this indication, backed by clinical data demonstrating significant improvements in symptoms and patient outcomes.

List of Key Companies in Intravenous Iron Drugs Market:

• AbbVie Inc.
• Covis Pharma GmbH.
• Daiichi Sankyo, Inc.
• Sanofi
• CSL Vifor
• PHARMACOSMOS A/S
• Zydus Lifesciences Limited
• Cadila Pharmaceuticals
• Sandoz AG
• AdvaCare Pharma
• SHREEJI PHARMA INTERNATIONAL
• Livealth
• Reddy’s Laboratories Ltd.
• Pace Biotech
• Matinspharma

Recent Developments (Clinical Study/Product Launch)

• In August 2024, Pharmacosmos initiated a large-scale clinical study program in the U.S. to obtain FDA approval for Monofer. The program consists of two major trials, FERWONIDA for iron deficiency anaemia patients and FERWONNEPHRO for non-dialysis dependent chronic kidney disease patients,enrolling 3,000 participants. These studies aim to demonstrate Monofer’s superior efficacy and safety, supporting its U.S. market entry and complementing ongoing global research.
• In March 2024, Cadila Pharmaceuticals launched Redshot FCM, an advanced intravenous iron injection for treating iron deficiency anemia in adults and children over one year of age, particularly those intolerant to oral iron. Redshot offers rapid iron replenishment with superior safety and minimal ranaphylaxis risk, addressing unmet needs in anemia management.